AFQ056
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyskinesias
Conditions
Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders, Anti-Dyskinesia Agents
Trial Timeline
Mar 1, 2012 → Oct 1, 2013
NCT ID
NCT01491932About AFQ056
AFQ056 is a phase 2 stage product being developed by Novartis for Dyskinesias. The current trial status is completed. This product is registered under clinical trial identifier NCT01491932. Target conditions include Dyskinesias, Parkinson Disease, Movement Disorders.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01491932 | Phase 2 | Completed |
| NCT01482143 | Phase 1 | Completed |
| NCT01433354 | Phase 2/3 | Terminated |
| NCT01348087 | Phase 2 | Terminated |
| NCT01456663 | Phase 1 | Completed |
| NCT01442259 | Phase 1 | Completed |
| NCT01173731 | Phase 2 | Completed |
| NCT00414856 | Phase 1 | Completed |
Competing Products
4 competing products in Dyskinesias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levodopa-carbidopa intestinal gel | AbbVie | Phase 3 | 77 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| AQW051 + AQW051 + Placebo | Novartis | Phase 2 | 52 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |